Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA2B | P08514 | 1/20 | 0.49 |
| ▸ | GBA1 | P04062 | 3/20 | 0.49 |
| ▸ | MOK | Q9UQ07 | 2/20 | 0.49 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 1/20 | 0.47 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.47 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GLA | P06280 | 1/20 | 0.47 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4604862 | 0.87 | PIK3CA (0.58) | ITGA2BGBA1PIK3CAMAPTHSD17B10 | |
| SCHEMBL4603008 | 0.85 | PIK3CA (0.53) | ITGA2BGBA1PIK3CAMAPTGLA | |
| SCHEMBL4938514 | 0.85 | PIK3CA (0.53) | ITGA2BGBA1PIK3CAMAPTGLA | |
| SCHEMBL4604545 | 0.83 | PIK3CA (0.51) | ITGA2BGBA1PIK3CAMAPTHSD17B10 | |
| SCHEMBL1262425 | 0.82 | ITGA2B (0.51) | ITGA2BGBA1PIK3CAMAPTLMNA | |
| SCHEMBL1263343 | 0.81 | ITGA2B (0.49) | ITGA2BGBA1PIK3CAMAPTMEN1 | |
| SCHEMBL4602973 | 0.80 | PIK3CA (0.65) | BRAFPIK3CAPIK3C2BMAPTHSD17B10 | |
| SCHEMBL27685989 | 0.80 | MEN1 (0.46) | PIK3CAMAPTMEN1KMT2APIP5K1C | |
| SCHEMBL1264089 | 0.80 | ITGA2B (0.44) | ITGA2BGBA1BRAFPIK3CAMAPT | |
| SCHEMBL27701926 | 0.80 | NPC1 (0.48) | ITGA2BGBA1BRAFLMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1768978-B1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-07-09 | — | — | EP | disclosed |
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | ASTRAZENECA AB (SE) | 2008-03-06 | — | — | US | disclosed |
| CN-101014590-A | 2,4, 6-trisubstituted pyrimidines as Phosphatidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer | ASTRAZENECA AB (SE) | 2007-08-08 | — | — | CN | disclosed |
| EP-1768978-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-04-04 | — | — | EP | disclosed |
| WO-2006005914-A1 | 2, 4, 6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058332-A1 | 2,4,6-Trisubstituted Pyrimidines as Phosphotidylinositol (Pi) 3-Kinase Inhibitors and Their Use in the Treatment of Cancer | PIK3CA, TYMP, PIK3CB | ITGA2B 2965/4885GBA1 2888/4885MOK 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.